miRNA’s inherent stability, easy methods for quantification (qRT-PCR), and relatively easy detection within bodily fluids (such as serum, saliva, semen, and urine) make them promising tools to improve the accuracy of current available diagnostic modalities in PCa such as prostate-specific antigen (PSA), digital rectal exam (DRE), and sonography tests (Bidarra et al., 2019). The gene discussed is PROS1; the disease is posterior cortical atrophy.